Serum soluble BCMA can be used to monitor relapse of multiple myeloma patients after chimeric antigen receptor T-cell immunotherapy
- 12 January 2023
- journal article
- research article
- Published by Elsevier in Current Research in Translational Medicine
- Vol. 71 (2) , 103378
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyondLeukemia, 2017
- Soluble TACI and soluble BCMA as biomarkers in primary central nervous system lymphomaNeuro-Oncology, 2017
- γ-secretase directly sheds the survival receptor BCMA from plasma cellsNature Communications, 2015
- Overestimation of free light chain antigen excess rateClinica Chimica Acta, 2015
- Current concepts in the diagnosis and management of cytokine release syndromeBlood, 2014
- Multiple myelomaAnnals of Oncology, 2010
- Receiver Operating Characteristic Curve in Diagnostic Test AssessmentJournal of Thoracic Oncology, 2010
- Structure and function of immunoglobulinsJournal of Allergy and Clinical Immunology, 2010
- Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failureBMC Nephrology, 2008
- Pathogenesis and treatment of renal failure in multiple myelomaLeukemia, 2008